Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Median progression-free survival (PFS), duration of response (DOR), and... | Download Scientific Diagram
Progression-Free Survival for WM | IMBRUVICA® (ibrutinib)
NEJM on Twitter: "KEYNOTE-836: In advanced cervical cancer, median PFS was 10.4 months with pembrolizumab and 6 months with placebo. Overall survival at 2 years was 50.4% and 40.4%, respectively. #ESMO21 https://t.co/sZd6SFiGKd
Median overall survival (OS) and progression-free survival (PFS) in a... | Download Scientific Diagram
OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH.... EHA Library. Harrison C. Jun 9 2021; 324611
Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram
KRd vs Rd Study Results & Efficacy | KYPROLIS® (carfilzomib)
JCM | Free Full-Text | A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation | HTML
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis | PLOS ONE
Overall survival and progression-free survival. The median follow-up... | Download Scientific Diagram
IMFINZI® (durvalumab) Efficacy & Clinical Trials for ES-SCLC
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
Diagnostics | Free Full-Text | Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Progression Free Survival Curve. Median PFS 4.5 months 95% CI 3.5–5.3.... | Download Scientific Diagram
a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram
Progression-free survival (PFS) and overall survival (OS) time. Median... | Download Scientific Diagram
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
REVEL Trial Progression-Free Survival for mNSCLC | CYRAMZA® (ramucirumab)
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Kaplan-Meier curves of progression-free survival (PFS) and overall... | Download Scientific Diagram
